Literature DB >> 28528405

Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies.

D R Giacobbe1, A E Maraolo2, C Viscoli3.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28528405     DOI： 10.1007/s10096-017-3010-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  14 in total

1.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Francesco Giuseppe De Rosa; Maddalena Giannella; Daniele Roberto Giacobbe; Matteo Bassetti; Angela Raffaella Losito; Michele Bartoletti; Valerio Del Bono; Silvia Corcione; Giuseppe Maiuro; Sara Tedeschi; Luigi Celani; Chiara Simona Cardellino; Teresa Spanu; Anna Marchese; Simone Ambretti; Roberto Cauda; Claudio Viscoli; Pierluigi Viale
Journal:  J Antimicrob Chemother       Date:  2015-04-21       Impact factor: 5.790

2.  Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?

Authors:  Federico Pea; Paola Della Siega; Piergiorgio Cojutti; Assunta Sartor; Massimo Crapis; Claudio Scarparo; Matteo Bassetti
Journal:  Int J Antimicrob Agents       Date:  2016-12-08       Impact factor: 5.283

3.  Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?

Authors:  Valerio Del Bono; Daniele Roberto Giacobbe; Anna Marchese; Andrea Parisini; Carmen Fucile; Erika Coppo; Valeria Marini; Antonio Arena; Alexandre Molin; Antonietta Martelli; Angelo Gratarola; Claudio Viscoli; Paolo Pelosi; Francesca Mattioli
Journal:  Virulence       Date:  2016-07-18       Impact factor: 5.882

4.  Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.

Authors:  M Souli; I Karaiskos; A Masgala; L Galani; E Barmpouti; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-16       Impact factor: 3.267

Review 5.  Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.

Authors:  Enrico Maria Trecarichi; Mario Tumbarello
Journal:  Virulence       Date:  2017-02-08       Impact factor: 5.882

6.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

Review 7.  Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.

Authors:  Oren Zusman; Sergey Altunin; Fidi Koppel; Yael Dishon Benattar; Habip Gedik; Mical Paul
Journal:  J Antimicrob Chemother       Date:  2016-09-13       Impact factor: 5.790

8.  Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.

Authors:  George L Daikos; Sophia Tsaousi; Leonidas S Tzouvelekis; Ioannis Anyfantis; Mina Psichogiou; Athina Argyropoulou; Ioanna Stefanou; Vana Sypsa; Vivi Miriagou; Martha Nepka; Sarah Georgiadou; Antonis Markogiannakis; Dimitris Goukos; Athanasios Skoutelis
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

Review 9.  Combination therapy for carbapenem-resistant Gram-negative bacteria.

Authors:  Mical Paul; Yehuda Carmeli; Emanuele Durante-Mangoni; Johan W Mouton; Evelina Tacconelli; Ursula Theuretzbacher; Cristina Mussini; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2014-05-28       Impact factor: 5.790

Review 10.  Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.

Authors:  Oren Zusman; Tomer Avni; Leonard Leibovici; Amos Adler; Lena Friberg; Theodouli Stergiopoulou; Yehuda Carmeli; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191
View more
  4 in total

1.  Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.

Authors:  Matteo Bassetti; Daniele Roberto Giacobbe; Niki Patel; Glenn Tillotson; Jill Massey
Journal:  Adv Ther       Date:  2019-05-16       Impact factor: 3.845

2.  Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study.

Authors:  Astrid V Cienfuegos-Gallet; Ana M Ocampo de Los Ríos; Patricia Sierra Viana; Faiver Ramirez Brinez; Carlos Restrepo Castro; Gustavo Roncancio Villamil; Helena Del Corral Londoño; J Natalia Jiménez
Journal:  BMC Infect Dis       Date:  2019-10-07       Impact factor: 3.090

3.  Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Pneumonia.

Authors:  HyeJin Shi; Jin Seo Lee; So Yeon Park; Yousang Ko; Joong Sik Eom
Journal:  Infect Drug Resist       Date:  2019-12-23       Impact factor: 4.003

4.  Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018.

Authors:  Paolo Gaibani; Donatella Lombardo; Linda Bussini; Federica Bovo; Beatrice Munari; Maddalena Giannella; Michele Bartoletti; Pierluigi Viale; Tiziana Lazzarotto; Simone Ambretti
Journal:  Antibiotics (Basel)       Date:  2021-05-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.